EA012264B1 - Фармацевтические композиции, основанные на антагонистах nk2, для применения в педиатрической практике - Google Patents
Фармацевтические композиции, основанные на антагонистах nk2, для применения в педиатрической практике Download PDFInfo
- Publication number
- EA012264B1 EA012264B1 EA200700949A EA200700949A EA012264B1 EA 012264 B1 EA012264 B1 EA 012264B1 EA 200700949 A EA200700949 A EA 200700949A EA 200700949 A EA200700949 A EA 200700949A EA 012264 B1 EA012264 B1 EA 012264B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cyclo
- antagonist
- rye
- antagonists
- eey
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 206010021746 Infantile colic Diseases 0.000 claims abstract description 3
- 108010092101 MEN 11420 Proteins 0.000 claims description 16
- NGCNKEZHGRXHNL-WVWQGFTISA-N n-[(2r,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-[(1s,4s,7s,10s,13s,16s)-13-benzyl-16-(1h-indol-3-ylmethyl)-7-(2-methylpropyl)-3,6,9,12,15,18,20-heptaoxo-2,5,8,11,14,17,21-heptazabicyclo[8.8.4]docosan-4-yl]acetamide Chemical compound C([C@H]1C(=O)N[C@H]2CC(=O)NC[C@H](NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC2=O)C(=O)N[C@H](C(N1)=O)CC(C)C)C(=O)N[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O NGCNKEZHGRXHNL-WVWQGFTISA-N 0.000 claims description 16
- 229950000640 nepadutant Drugs 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 239000002462 tachykinin receptor antagonist Substances 0.000 claims description 9
- 102000003141 Tachykinin Human genes 0.000 claims description 7
- 108060008037 tachykinin Proteins 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 208000002881 Colic Diseases 0.000 abstract description 17
- 208000004998 Abdominal Pain Diseases 0.000 description 16
- 230000000968 intestinal effect Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000000556 agonist Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000010199 sorbic acid Nutrition 0.000 description 5
- 229940075582 sorbic acid Drugs 0.000 description 5
- 239000004334 sorbic acid Substances 0.000 description 5
- 230000009278 visceral effect Effects 0.000 description 5
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- 208000035154 Hyperesthesia Diseases 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- -1 polysiloxanes Polymers 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 235000011034 Rubus glaucus Nutrition 0.000 description 3
- 244000235659 Rubus idaeus Species 0.000 description 3
- 235000009122 Rubus idaeus Nutrition 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000008991 intestinal motility Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000001314 paroxysmal effect Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000009935 visceral pain Diseases 0.000 description 2
- KQRBOHOKLNORTA-UHFFFAOYSA-N 6-methyl-1-benzothiophene-2-carboxylic acid Chemical compound CC1=CC=C2C=C(C(O)=O)SC2=C1 KQRBOHOKLNORTA-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 101800000399 Neurokinin A Proteins 0.000 description 1
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 1
- 102400000097 Neurokinin A Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 206010038731 Respiratory tract irritation Diseases 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 206010043169 Tearfulness Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000002741 bronchospastic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000004090 etiopathogenesis Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002325 prokinetic agent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000221A ITFI20040221A1 (it) | 2004-10-27 | 2004-10-27 | Composizioni farmaceutiche a base di nk2 antagonisti per uso pediatrico |
| PCT/EP2005/055575 WO2006045820A1 (en) | 2004-10-27 | 2005-10-26 | Pharmaceutical compositions based on nk2 antagonists for pediatric use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200700949A1 EA200700949A1 (ru) | 2007-10-26 |
| EA012264B1 true EA012264B1 (ru) | 2009-08-28 |
Family
ID=35613882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200700949A EA012264B1 (ru) | 2004-10-27 | 2005-10-26 | Фармацевтические композиции, основанные на антагонистах nk2, для применения в педиатрической практике |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7727955B2 (enExample) |
| EP (1) | EP1809267B1 (enExample) |
| JP (1) | JP2008517977A (enExample) |
| CN (1) | CN101052386A (enExample) |
| AR (1) | AR051595A1 (enExample) |
| AT (1) | ATE422881T1 (enExample) |
| AU (1) | AU2005298629B2 (enExample) |
| CA (1) | CA2584481C (enExample) |
| CY (1) | CY1109803T1 (enExample) |
| DE (1) | DE602005012857D1 (enExample) |
| DK (1) | DK1809267T3 (enExample) |
| EA (1) | EA012264B1 (enExample) |
| ES (1) | ES2325413T3 (enExample) |
| HR (1) | HRP20090225T1 (enExample) |
| IT (1) | ITFI20040221A1 (enExample) |
| MX (1) | MX2007004461A (enExample) |
| NO (1) | NO338586B1 (enExample) |
| NZ (1) | NZ555380A (enExample) |
| PL (1) | PL1809267T3 (enExample) |
| PT (1) | PT1809267E (enExample) |
| RS (1) | RS50780B (enExample) |
| SI (1) | SI1809267T1 (enExample) |
| UA (1) | UA91988C2 (enExample) |
| WO (1) | WO2006045820A1 (enExample) |
| ZA (1) | ZA200703909B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0614970D0 (en) * | 2006-07-27 | 2006-09-06 | R & D Sosei Ltd | Compounds For Use In Therapy |
| IT1394304B1 (it) * | 2009-05-21 | 2012-06-06 | Malesci Sas | Processo per la preparazione di ibodutant (men15596) e relativi intermedi |
| ITRM20120331A1 (it) * | 2012-07-12 | 2014-01-13 | Guidotti & C Spa Labor | Composizioni pediatriche orali liquide contenenti nepadutant. |
| US20160051596A1 (en) * | 2014-08-21 | 2016-02-25 | Food Industry Research And Development Institute | Novel acetobacter and gluconacetobacter strains and their metabolites for use in inhibiting xanthine oxidase |
| US9867857B2 (en) | 2014-08-21 | 2018-01-16 | Food Industry Research And Development Institute | Acetobacter and gluconacetobacter strains and their metabolites for use in inhibiting xanthine oxidase |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996028467A1 (en) * | 1995-03-13 | 1996-09-19 | A. Menarini Industrie Farmaceutiche Riunite S.R.L. | Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical composition |
| WO2001029066A2 (en) * | 1999-10-21 | 2001-04-26 | Menarini Ricerche S.P.A. | Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them |
| WO2003037916A2 (en) * | 2001-10-29 | 2003-05-08 | Malesci Istituto Farmacobiologico S.P.A. | Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| WO2004037266A1 (en) * | 2002-10-24 | 2004-05-06 | Novartis Ag | Compounds for the treatment of cough |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0219318A (ja) * | 1988-06-30 | 1990-01-23 | Carl R Thornfeldt | 疝痛及び生歯に対する治療 |
-
2004
- 2004-10-27 IT IT000221A patent/ITFI20040221A1/it unknown
-
2005
- 2005-10-24 AR ARP050104429A patent/AR051595A1/es unknown
- 2005-10-26 CA CA2584481A patent/CA2584481C/en not_active Expired - Fee Related
- 2005-10-26 DK DK05810894T patent/DK1809267T3/da active
- 2005-10-26 RS RSP-2009/0169A patent/RS50780B/sr unknown
- 2005-10-26 ES ES05810894T patent/ES2325413T3/es not_active Expired - Lifetime
- 2005-10-26 EP EP05810894A patent/EP1809267B1/en not_active Expired - Lifetime
- 2005-10-26 JP JP2007538414A patent/JP2008517977A/ja active Pending
- 2005-10-26 PL PL05810894T patent/PL1809267T3/pl unknown
- 2005-10-26 EA EA200700949A patent/EA012264B1/ru not_active IP Right Cessation
- 2005-10-26 AU AU2005298629A patent/AU2005298629B2/en not_active Ceased
- 2005-10-26 SI SI200530661T patent/SI1809267T1/sl unknown
- 2005-10-26 US US11/666,204 patent/US7727955B2/en not_active Expired - Fee Related
- 2005-10-26 WO PCT/EP2005/055575 patent/WO2006045820A1/en not_active Ceased
- 2005-10-26 UA UAA200705837A patent/UA91988C2/ru unknown
- 2005-10-26 MX MX2007004461A patent/MX2007004461A/es active IP Right Grant
- 2005-10-26 HR HR20090225T patent/HRP20090225T1/xx unknown
- 2005-10-26 PT PT05810894T patent/PT1809267E/pt unknown
- 2005-10-26 AT AT05810894T patent/ATE422881T1/de active
- 2005-10-26 NZ NZ555380A patent/NZ555380A/en not_active IP Right Cessation
- 2005-10-26 CN CNA2005800370703A patent/CN101052386A/zh active Pending
- 2005-10-26 DE DE602005012857T patent/DE602005012857D1/de not_active Expired - Lifetime
-
2007
- 2007-05-15 ZA ZA200703909A patent/ZA200703909B/xx unknown
- 2007-05-29 NO NO20072720A patent/NO338586B1/no not_active IP Right Cessation
-
2009
- 2009-05-07 CY CY20091100493T patent/CY1109803T1/el unknown
-
2010
- 2010-04-19 US US12/799,176 patent/US20100234284A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996028467A1 (en) * | 1995-03-13 | 1996-09-19 | A. Menarini Industrie Farmaceutiche Riunite S.R.L. | Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical composition |
| WO2001029066A2 (en) * | 1999-10-21 | 2001-04-26 | Menarini Ricerche S.P.A. | Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them |
| WO2003037916A2 (en) * | 2001-10-29 | 2003-05-08 | Malesci Istituto Farmacobiologico S.P.A. | Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| WO2004037266A1 (en) * | 2002-10-24 | 2004-05-06 | Novartis Ag | Compounds for the treatment of cough |
Non-Patent Citations (1)
| Title |
|---|
| GIULIANI S. ET AL.: "EFFECT OF A TACHYKININ NK2 RECEPTOR ANTAGONIST, NEPADUTANT, ON CARDIOVASCULAR AND GASTROINTESTINAL FUNCTION IN RATS AND DOGS", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 415, 2001, pages 61-71, XP002945503, ISSN: 0014-2999, abstract * |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20072720L (no) | 2007-07-09 |
| US20080090795A1 (en) | 2008-04-17 |
| CN101052386A (zh) | 2007-10-10 |
| EA200700949A1 (ru) | 2007-10-26 |
| ITFI20040221A1 (it) | 2005-01-27 |
| ATE422881T1 (de) | 2009-03-15 |
| NO338586B1 (no) | 2016-09-12 |
| HRP20090225T1 (hr) | 2009-05-31 |
| EP1809267B1 (en) | 2009-02-18 |
| RS50780B (sr) | 2010-08-31 |
| CY1109803T1 (el) | 2014-09-10 |
| EP1809267A1 (en) | 2007-07-25 |
| PT1809267E (pt) | 2009-05-28 |
| DE602005012857D1 (de) | 2009-04-02 |
| SI1809267T1 (sl) | 2009-06-30 |
| AU2005298629B2 (en) | 2011-02-17 |
| MX2007004461A (es) | 2007-07-11 |
| ZA200703909B (en) | 2008-09-25 |
| UA91988C2 (ru) | 2010-09-27 |
| DK1809267T3 (da) | 2009-05-18 |
| CA2584481C (en) | 2014-07-15 |
| AU2005298629A1 (en) | 2006-05-04 |
| PL1809267T3 (pl) | 2009-07-31 |
| US20100234284A1 (en) | 2010-09-16 |
| ES2325413T3 (es) | 2009-09-03 |
| HK1109335A1 (en) | 2008-06-06 |
| US7727955B2 (en) | 2010-06-01 |
| WO2006045820A1 (en) | 2006-05-04 |
| JP2008517977A (ja) | 2008-05-29 |
| NZ555380A (en) | 2008-12-24 |
| CA2584481A1 (en) | 2006-05-04 |
| AR051595A1 (es) | 2007-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20060130175A (ko) | 미다졸람을 고농도로 포함하는 제약학적 조성물 | |
| JP2711759B2 (ja) | 止瀉剤組成物 | |
| US20250161333A1 (en) | Compositions and methods for treating epilepsy | |
| US20180028550A1 (en) | Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome | |
| EA012264B1 (ru) | Фармацевтические композиции, основанные на антагонистах nk2, для применения в педиатрической практике | |
| CZ294070B6 (cs) | Perorální vodný roztok, obsahující jako aktivní složku 4-amino-5-chlor-2,3-dihydro-N- [1-(3-metoxypropyl)-4-piperi-dyl]-7-benzofurankarboxamid | |
| JPS5938203B2 (ja) | 補酵素ｑを主成分とする脳循環障害治療剤 | |
| KR20110071096A (ko) | 기능성 소화관 장해의 예방 및/또는 치료제 | |
| WO2000074685A1 (fr) | Preparations orales d'etidronate disodique | |
| KR101726513B1 (ko) | 실리비닌을 유효성분으로 포함하는 뇌전증의 예방 또는 치료용 조성물 | |
| US20250032516A1 (en) | Compositions and methods for treating epilepsy | |
| KR102489247B1 (ko) | 리나릴 아세테이트를 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물 | |
| WO2020085612A1 (ko) | 크레아틴 및 타우린의 혼합물을 함유하는 우울장애 및 불안장애의 치료용 약학적 조성물 | |
| KR102473858B1 (ko) | 시력 증강 목적을 갖는 자일라진의 용도 | |
| JP2019006717A (ja) | 経口睡眠改善剤 | |
| HK1109335B (en) | Pharmaceutical compositions based on nk2 antagonists for pediatric use | |
| JP6935930B2 (ja) | 生薬成分を含む肺高血圧症の予防又は治療剤 | |
| KR20250151401A (ko) | 말초 신경 장애의 치료 또는 예방을 위한 의약 | |
| JP2024505539A (ja) | ラクトバチルス・パラカゼイ由来小胞を含むウイルス感染疾患または呼吸器疾患の予防、治療、または改善用組成物 | |
| KR20240063495A (ko) | 탈람파넬을 포함하는 스트레스 및 우울증 관련 질환의 개선, 예방 또는 치료용 조성물 | |
| KR20250021128A (ko) | 세레브로리진을 유효성분으로 포함하는 근육질환의 예방 또는 치료용 조성물 | |
| RU2546300C1 (ru) | Композиция, обладающая действием на центральную нервную систему и ее применение | |
| KR20210135835A (ko) | 움벨리페론을 유효성분으로 함유하는 외상 후 스트레스장애 예방 또는 치료용 조성물 | |
| JP2022529290A (ja) | 呼吸性不整脈を処置するための方法および組成物 | |
| KR20000074867A (ko) | 발기부전 치료용 조성물 (2) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |